Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation frequently occurs in CRC patients, which shows a guiding significance for anti-EGFR targeted therapy such as cetuximab and panitumumab.[113] A study suggested that IGF2BP2 can bind with KRAS to regulate its expression.[114] This result indicates that IGF2BP2 may involve in anti-EGFR targeted therapy in CRC. Here, IGF2BP2 is linked to colorectal carcinoma.